Sagent Pharmaceuticals announced the FDA approval of Indocyanine Green (NDA 218579), expanding its portfolio of critical diagnostic products for the interstitial route. This market-moving approval strengthens the company’s position in the access catheter and contrast agent sectors, likely enhancing revenue potential in the intravascular diagnostic space.